Pharmacology of Respiratory and Asthma Drugs

The Sympathetic Nervous System (SNS)

The SNS governs the "fight or flight" response. In the respiratory system, SNS activation results in the relaxation of smooth muscle (bronchodilation) and an increased respiratory rate. This pathway is the primary target for rapid-acting rescue medications.

Bronchodilators: Reversing Bronchoconstriction

Bronchodilators are designed to relax the airway smooth muscle to improve airflow immediately or prevent it from closing. There are three main classes:

1. Beta-2 ($\beta_2$) Receptor Agonists

These are often the first-line treatment for asthma. They work by stimulating $\beta_2$ receptors located directly on the lung smooth muscle. This stimulation increases levels of cyclic AMP (cAMP), which signals the muscle to relax.

• Short-acting (SABA): e.g., Salbutamol (used "as needed" for acute symptoms).
• Long-acting (LABA): e.g., Salmeterol (used for prevention).

Exam Tip: Remember that while $\beta_2$ agonists are excellent at relaxing smooth muscle, they have no effect on the underlying hyperreactivity or inflammation of the airways.

2. Anticholinergics

These act as muscarinic receptor antagonists. By blocking the parasympathetic signal, they prevent the smooth muscle from constricting further. Examples include ipratropium and tiotropium.

3. Xanthine Drugs

Drugs like theophylline work by inhibiting the enzyme phosphodiesterase (PDE). By inhibiting PDE, the levels of cAMP (the "relax" signal) remain high in the smooth muscle, promoting bronchodilation.

Anti-inflammatory Drugs: Targeting the Root Cause

While bronchodilators treat the symptoms of constriction, anti-inflammatory drugs treat the cause of the airway sensitivity.

• Corticosteroids (Glucocorticoids): These are essential for moderate to severe asthma. They work by modifying gene transcription to increase anti-inflammatory mediators and decrease pro-inflammatory mediators.
• Leukotriene Antagonists: These drugs (e.g., montelukast) specifically block the bronchoconstrictor action of leukotrienes released from inflammatory cells, thereby reducing hyper-reactivity.
• Mast Cell Stabilizers: Medications like Cromolyn Sodium aim to prevent the release of histamine from mast cells, though their exact mechanism in asthma is still considered somewhat unclear.
• Anti-IgE Antibodies: A biological approach using monoclonal antibodies (e.g., omalizumab) to bind to IgE, preventing it from triggering mast cells and basophils.

Clinical Management and Treatment Strategies

Asthma treatment follows a "step-care" pathway. As a patient's symptoms increase in frequency or intensity, the pharmacological approach must be expanded.

The goal of therapy is always to decrease the intensity and frequency of symptoms while maintaining the patency of the bronchial tubes. If a patient is well-controlled for at least 3 months, clinicians may consider "step-down" therapy to reduce drug reliance.

Clinical Caution: When prescribing, always monitor for side effects. For example, $\beta_2$ agonists can cause tremors and tachycardia, while prolonged use of systemic corticosteroids can lead to Cushing’s syndrome or loss of bone density.